The article "Switching Patients with Schizophrenia from Intramuscular Paliperidone Palmitate Once Monthly to TV-46000, a Long-Acting Subcutaneous Antipsychotic: Population Pharmacokinetic-Based Strategies" explores strategies for transitioning patients with schizophrenia from the intramuscular formulation of paliperidone palmitate (PP1m) to a new long-acting subcutaneous formulation, TV-46000 (risperidone), which can be administered either monthly or every two months.
The findings suggest that clinicians can effectively switch patients to TV-46000 while maintaining similar drug exposure levels, thus minimizing the risk of significant variations in active drug concentrations. Ultimately, the decision to switch should consider patient preferences, convenience, and potential concerns about tolerability or symptom recurrence.
For more details, you can access the full article here.
Recent Posts
- Healthcare costs and use before and after opioid overdose in Veterans Health Administration patients with opioid use disorder
- The Rise of AI Companions and What it Means for Youth Mental Health
- The Neuropsychiatry Brief — Edition 18 Circuit Psychiatry: TMS, theta burst, accelerated protocols, and why the delivery system may be the treatment
